Physician profile
Yonide Lareche
NPI 1639535073
$484.47
in general payments reported to CMS, 2019-2025
10 companies · $88.47 in 2025
The $88.47 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.52 · 2022: $86.21 · 2023: $276 · 2024: $22.25 · 2025: $88.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $382 · Education: $4.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $382.21 |
| Education | $4.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $240.22 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $63.01 | 2023 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $29.96 | 2023 | Trintellix |
| Indivior INC. | $29.96 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.58 | 2022 | |
| Axsome Therapeutics, INC. | $24.93 | 2023 | Auvelity |
| Abbvie INC. | $22.88 | 2023 | |
| Vertical Pharmaceuticals, LLC | $22.25 | 2024 | Relexxii |
| Alkermes, INC. | $12.16 | 2022 | |
| Supernus Pharmaceuticals, INC. | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yonide Lareche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.